Indivior lawsuits remain one of the most watched pharmaceutical enforcement actions in recent years. The company’s legal history involves fraud settlements, antitrust claims, and federal investigations. Courts and regulators accuse Indivior of prioritizing profits over patient safety.
Moreover, Indivior lawsuits highlight patterns of misconduct that continue to affect patient health today. (If you lost teeth after taking opioid-dependence medication, contact us about filing a Suboxone lawsuit.)
The Corporate Entity
Indivior is a global pharmaceutical company headquartered in the United Kingdom. The company develops medications for addiction treatment and mental health disorders.
Indivior emerged in 2014 as a spin-off from Reckitt Benckiser, a multinational consumer goods company. The separation allowed Indivior to operate independently while focusing heavily on its flagship opioid treatment products.
Since its launch, Indivior has relied on Suboxone and related medications as primary revenue drivers. This dependence shaped both the company’s growth and its legal challenges.
Indivior’s 2019 Federal Fraud Lawsuit Settlement
In 2019, Indivior reached one of the largest pharmaceutical settlements in U.S. history. The company agreed to pay $1.4 billion to resolve allegations of false marketing.
Federal and state prosecutors accused Indivior of promoting Suboxone Film as safer than alternatives without scientific proof. Authorities also claimed the company used misleading strategies to maintain market dominance.
The Department of Justice described Indivior’s conduct as a scheme that put vulnerable patients at risk. The settlement involved criminal penalties, civil claims, and resolutions with state Medicaid programs. Follow this list for the Reuters news report.
2020 Criminal Penalties
In 2020, Indivior entered additional agreements with the U.S. Department of Justice. The company paid $600 million to settle criminal and civil liability tied to Suboxone.
Court documents revealed that Indivior misled healthcare providers about safety claims. Prosecutors argued that these tactics harmed patients and defrauded government healthcare programs.
The settlement resolved multiple charges while allowing Indivior to continue operations under strict compliance monitoring.
Indivior Antitrust Lawsuit Allegations
Indivior has also faced antitrust lawsuits in U.S. federal courts. Plaintiffs allege that the company engaged in “product hopping” to block generic competition.
Indivior shifted marketing from Suboxone tablets to Suboxone films just as tablets neared generic expiration. This move, critics argue, aimed to extend exclusivity and maintain high prices.
Courts continue to review these claims, and several cases resulted in financial settlements.
Securities and Investor Claims
Beyond consumer and government litigation, Indivior also faced lawsuits from investors. Shareholders accused the company of concealing the scope of federal investigations.
Stock value dropped sharply after government enforcement actions became public. Securities lawsuits alleged that investors suffered losses due to misleading disclosures.
Corporate Reputation and Public Health Concerns
Indivior’s repeated legal challenges raise questions about its corporate culture. Regulators highlight patterns of aggressive marketing, questionable disclosures, and delayed warnings.
Public health experts argue that companies developing addiction treatments carry heightened responsibility. Critics say Indivior’s legal history reflects a failure to balance profit with patient safety.
Indivior Today
Indivior remains active in global pharmaceutical markets. The company continues to market opioid treatment products and expand into mental health medications.
Despite ongoing litigation, Indivior reported strong revenues in recent years. Suboxone Film remains central to its portfolio. The company now faces lawsuits from patients alleging undisclosed dental injuries.
Why Indivior Lawsuits Matter
Indivior lawsuits reveal how pharmaceutical misconduct affects patients, taxpayers, and investors. Large settlements show the financial risks of corporate wrongdoing.
Legal actions also influence future industry conduct. Court oversight, compliance agreements, and regulatory monitoring attempt to reform Indivior’s practices.
Conclusion
Indivior’s legal history includes multibillion-dollar fraud settlements, antitrust cases, and criminal penalties. The company continues to face lawsuits connected to its leading products.
Indivior’s track record demonstrates the importance of corporate accountability in the pharmaceutical industry. Patients, regulators, and investors continue to scrutinize the company’s actions.
